JERUSALEM, March 20 (Xinhua) -- Researchers in Israel have tested a potential treatment for chronic kidney disease (CKD) in dogs, the Hebrew University of Jerusalem said on Thursday.
A study published in the Journal of Veterinary Internal Medicine examined the effects of paricalcitol, a synthetic form of vitamin D, on two common CKD complications: renal secondary hyperparathyroidism (RHPT) and proteinuria, or excess protein in urine.
CKD is a progressive condition that leads to kidney failure, primarily affecting older dogs but also occurring in younger ones. RHPT develops when damaged kidneys fail to regulate minerals like calcium and phosphorus, causing elevated parathyroid hormone (PTH) levels that can weaken bones and harm organs.
The trial involved 13 dogs with CKD, treated with either paricalcitol or a placebo over two 12-week periods. Researchers found that proteinuria worsened in dogs given a placebo but remained stable in those receiving paricalcitol, suggesting the drug may help protect kidney function.
Some treated dogs experienced mild increases in calcium levels, though dose adjustments helped manage the condition.
While the findings are encouraging, further studies are needed to assess the long-term safety and effectiveness of the treatment. ■
